Functional polymorphisms of the lncRNA H19 promoter region contribute to the cancer risk and clinical outcomes in advanced colorectal cancer

Table 4 MDR analysis for the prediction of prognosis with and without 3 SNPs genotypes in advanced CRC patients

Best interaction models	DFS			OS
Best interaction models	Cross-validation consistency	P ^a	Training odds ratio	Cross-validation consistency	P ^a	Training odds ratio
1	81/100	0.0579	1.38 (0.99–1.92)	83/100	0.0317	1.82 (1.05–3.15)
1,2	65/100	0.0023	1.69 (1.21–2.38)	95/100	0.0032	2.27 (1.30–3.95)
1,2,3	100/100	< 0.0001	2.24 (1.59–3.17)	64/100	0.0001	3.08 (1.69–5.61)
1,2,3,4	100/100	< 0.0001	2.69 (1.91–3.78)	47/100	< 0.0001	4.92 (2.51–9.62)
1,2,3,4,5	100/100	< 0.0001	3.71 (2.61–5.26)	98/100	< 0.0001	14.30 (5.32–38.44)
1,2,3,4,5,6	93/100	< 0.0001	5.08 (3.55–7.27)	90/100	< 0.0001	27.10 (8.79–83.54)
1,2,3,4,5,6,7	61/100	< 0.0001	8.33 (5.63–12.33)	92/100	< 0.0001	71.88 (17.19–300.58)
1,2,3,4,5,6,7,8	100/100	< 0.0001	14.44 (9.40–22.16)	100/100	< 0.0001	∞
1,2,3,4,5,6,7,8,9	54/100	< 0.0001	23.49 (14.80–37.26)	100/100	< 0.0001	∞
1,2,3,4,5,6,7,8,9,10	100/100	< 0.0001	47.27 (27.59–81.01)	100/100	< 0.0001	∞
1,2,3,4,5,6,7,8,9,10,11	100/100	< 0.0001	85.18 (45.85–158.23)	100/100	< 0.0001	∞
1,2,3,4,5,6,7,8,9,10,11,12	100/100	< 0.0001	85.17 (45.84–158.0)	99/100	< 0.0001	∞

The best model with maximum cross-validation consistency and minimum prediction error rate was in italics
Labels: 1, age, years; 2, body weight; 3, gender; 4, smoking status; 5, first-degree family history of cancer; 6, tumor size (cm); 7, tumor differentiation; 8, clinical stage; 9, rs4930101; 10, rs2735970; 11, rs11042170; 12, combined genotypes
^aP value for 1000-fold permutation test

ISSN: 1475-2867